Avandia Marketing, Sales Practices and Products Liability Litigation
The causation theory linking Avandia (rosiglitazone) to cardiovascular events is supported by multiple FDA warnings, clinical trials, and meta-analyses. Evidence indicates that rosiglitazone increases the risk of myocardial infarction, heart failure, and stroke, especially with long-term use. Scientific studies, including NEJM and BMJ publications, demonstrate a significant association between the drug and adverse cardiovascular outcomes, establishing causation based on epidemiological and clinical data.
2
Pending actions
5,299
Total actions filed
Active
Status
10/16/2007
Established
Filing deadline
Active procedural deadlines include participation in ongoing mediations, with specific claims submission deadlines not publicly specified but implied to be ongoing as part of the case management process.
Who qualifies
Plaintiffs must have used Avandia during the period from January 1, 2005, through August 14, 2007, with evidence of exposure through medical records. Injury claims require documented diagnosis of cardiovascular events such as heart attacks or strokes, confirmed by medical records. Plaintiffs must submit a verified Plaintiff Fact Sheet, signed under penalty of perjury, demonstrating causation and exposure.
Products involved
- Avandia
- rosiglitazone
Alleged injuries
- cardiovascular events
- heart attacks
- strokes
- fatalities
Settlement landscape
Most cases have been settled, with an estimated total settlement amount exceeding $250 million for approximately 5,500 claims, averaging around $45,000 per case. The litigation is nearing resolution, with most cases dismissed or settled and bellwether trials scheduled for late 2025.
Lead counsel
- Hagens Berman Sobol Shapiro LLP
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
